Research Article

Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity

Table 7

Glucose-dependent insulinotropic polypeptide level changes after 24 weeks of treatment in different groups depending on BMI reduction.

BMI reductionAt baselineAfter 24 months value

Responders418.7 (369.2; 488.8)431.8 (392.4; 499.3)0.289
Nonresponders363.0 (241.5; 419.6)412.1 (296.2; 478.3)0.039